MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage MASON, Ohio --(BUSINESS WIRE)--Aug. 27, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA)
MASON, Ohio --(BUSINESS WIRE)--Aug. 26, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global
MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12 th at 8:30am ET MASON, Ohio --(BUSINESS WIRE)--Aug. 12, 2019-- AtriCure, Inc.
Worldwide revenue of $58.9 million – an increase of 13.7% year over year U.S. revenue of $47.2 million – an increase of 15.5% year over year International revenue of $11.7 million – an increase of 7.0% year over year MASON, Ohio --(BUSINESS WIRE)--Jul. 30, 2019-- AtriCure, Inc.
MASON, Ohio --(BUSINESS WIRE)--Jul. 17, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Canaccord Genuity 39 th Annual
MASON, Ohio --(BUSINESS WIRE)--Jul. 10, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2019 financial results on Tuesday, July 30, 2019 .
Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2019-- AtriCure, Inc.
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation MASON, Ohio --(BUSINESS WIRE)--Apr. 23, 2019-- AtriCure, Inc.
MASON, Ohio --(BUSINESS WIRE)--Apr. 4, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019 .
Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio --(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The
cryoSPHERE probe launched in United States , designed exclusively for post-operative pain block MASON, Ohio --(BUSINESS WIRE)--Feb. 12, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced
Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE ® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio --(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc.
MASON, Ohio --(BUSINESS WIRE)--Feb. 4, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday,
